Scientists have discovered the ‘genetic signatures’ of the most common form of bladder cancer – and it could open up the possibility of better-targeted treatment, according to research published today (13 November).
The study looked at non-invasive bladder cancer tumours which form in the lining of the bladder and have not spread to the bladder muscle.
According to the NHS, there are 10,000 new cases of bladder cancer diagnosed in the UK every year, more than half of which are non-invasive.
The researchers from the University of Leeds, who were funded by Yorkshire Cancer Research, found that there are two genetic variants or subtypes of these tumours.
At the moment, all patients with non-invasive bladder cancer are treated similarly but scientists believe by understanding the genetic mutations involved in each of the subtypes, more targeted therapies can be offered.
Lead investigator Professor Margaret Knowles, from the Leeds Institute of Cancer and Pathology, said: “We have already identified a vulnerability in the cancer cells of one of the genetic subtypes. Our aim is to see if we can develop an experimental compound that could exploit this vulnerability, with the eventual aim of developing a drug that would kill the cancer cells.
“Although these tumours are not usually life-threatening, they frequently recur and patients require long-term invasive monitoring and repeated surgery.
“Our improved ability to identify these specific molecular features of individual tumours should allow a more personalised approach to therapy and disease management in future.”
The research found that many of the genetic mutations in these tumours disrupt so-called tumour suppressor genes, which normally act to prevent cancers.
The genetic flaws that contribute to the development of the tumours are not inherited but accumulate throughout life, largely through exposure to environmental factors, including cigarette smoking.
Dr Kathryn Scott, Chief Executive at Yorkshire Cancer Research, commenting on the research findings, said: “This is a fantastic discovery that could change the way we treat bladder cancer. Personalised treatment is a particularly exciting area of cancer research.
“If we can understand the exact genetic make-up of a tumour, we can give patients specific treatments that could have a greater chance of success. By tailoring therapies to a patient’s personal needs, we can avoid prescribing unnecessary treatment that can severely affect their quality of life.”
Some gene mutations linked to gender
The study, published in the journal Cancer Cell, also found that women were more likely to have a defect on a specific tumour suppressor gene. Three-quarters of the tumour samples from women, 20 out of 27, had the defect – compared to 42 per cent of the samples from men (23 out of 55).
Professor Knowles says further research is needed to see why women are more likely to have this genetic fault, to discover whether they are more likely to be exposed to a particular cancer-causing agent or whether it relates to differences in the biology of male and female bladders.
This is one of the first studies to look at the genetics of early-stage bladder cancer. Most research focuses on aggressive bladder cancers but a lot of urology practice involves treating and monitoring people with non-invasive bladder cancer.
Notes to Editors
For more information on this story, please contact David Lewis at the University of Leeds press office on 0113 343 8059 or at email@example.com or on the press office out of hours’ number: 07712 389448
A copy of the paper will be available when the embargo is lifted and is available here.
University of Leeds
The University of Leeds is one of the largest higher education institutions in the UK, with more than 33,000 students from more than 150 different countries, and a member of the Russell Group of research-intensive universities.
We are a top 10 university for research and impact power in the UK, according to the 2014 Research Excellence Framework and in the top 100 for academic reputation in the QS World University Rankings 2018. Additionally, the University has been awarded a Gold rating by the Government’s Teaching Excellence Framework in 2017, recognising its ‘consistently outstanding’ teaching and learning provision. Twenty-four of our academics have been awarded National Teaching Fellowships – more than any other institution in England, Northern Ireland and Wales – reflecting the excellence of our teaching. www.leeds.ac.uk.
- Harrogate-based Yorkshire Cancer Research was founded in 1925 and is the largest independent regional cancer charity in England (Registered Charity 516898). We are not part of a national charity.
- We are committed to reducing the devastating impact of cancer on the lives of people living in Yorkshire.
- Our mission is to work in partnership, fund research and support initiatives that will help people in Yorkshire avoid, survive and cope with cancer.
- Current statistics show that 575 people are diagnosed with cancer in Yorkshire every week. Incidence and mortality rates are higher than the England average due to social deprivation, post-industrialisation and lifestyle choices but also availability of healthcare services and difficulties accessing early diagnostics, clinical trials and the latest treatments.
- We aim to:
- Be the leading authority on cancer in Yorkshire, understanding the problems and priorities in the region and sharing knowledge with partners.
- Raise awareness of cancer and how to prevent it by working in local communities, schools and colleges, sports clubs and with other health-related organisations.
- Promote screening programmes and fund research that can improve the diagnosis of cancer so we can detect and treat it at the earliest opportunity.
- Invest in innovative research projects at every stage of a cancer patient's journey.
- Campaign for fair and equal access to the very best healthcare services and a greater share of the money spent nationally on research.
- For further information, please visit www.yorkshirecancerresearch.org.uk or follow us on Facebook or Twitter